Home
Valuation

Work Area: Valuation

Stealthy biotech buys up patent portfolios in string of recent deals

Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months

Dealing with 5G disappointment

The latest wireless standard hasn’t yet found its ‘killer app’ for consumers, and it’s affecting licensing negotiations

The advantages of using hedonic regression to measure the value of standardised technologies

Hedonic regression is a dependable and impartial way to estimate the value of a standardised technology. Further, it can be applied to a range of products, especially those with multiple features.

Latest content

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment

03 December 2020

Auction of Gionee’s smartphone patents a reality check for China

IP assets of bankrupt firm, once a big local handset seller, changed hands at fire-sale prices

25 November 2020

In Blackberry patent sale, Canada sees loss of prestige not value creation opportunity

Possible deal comes during a period of concern in the country over loss of tech crown jewels, engineering talent and the bleeding of IP assets

20 November 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations

19 November 2020

Data is the new frontier in healthcare IP licensing, says award-winning TTO

IAM speaks to the tech transfer office of Oregon Health & Science University about the keys to success in university-industry deal-making

17 November 2020

Under sanctions pressure, Huawei sells off entry level smartphone brand to government

Company has sold its Honor handset unit to a consortium backed by local authorities in Shenzhen government, a move that will take a big chunk out of its sales figures

17 November 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation

10 November 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome

09 November 2020

Meet the IV veteran creating an IP licensing business in the pharma space

Connie Wan of Seattle Gummy Company talks to IAM about the lessons she learned at the mega-NPE

06 November 2020

Elite patent stocks fell in September but outperformed NASDAQ

The composite stock performance of the IAM/ktMINE US Patent Elite dipped though not by as much as most major exchanges

05 November 2020

Get unlimited access to all IAM content